Research Papers

Quality of Life Research

, Volume 4, Issue 6, pp 532-539

First online:

Measuring health-related quality of life in persons with genital herpes

  • D. WildAffiliated withMetris Research, The Boathouse, The Embankment
  • , D. PatrickAffiliated withCost and Outcomes Assessment Team, School of Public Health and Community Medicine, University of Washington, SC-37
  • , E. JohnsonAffiliated withDepartment of Epidemiology, School of Public Health, University of Washington, SC-36
  • , R. BerzonAffiliated withBurroughs Wellcome Co.
  • , A. WaldAffiliated withVirology Research Clinic, University of Washington, ZA-22

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


A disease-specific measure was needed for use in an international clinical trial to evaluate an investigational drug for genital herpes. A new measure was developed initially in the UK and translated and adapted for use in France, Italy, Germany, Denmark, Spain and the USA. This paper describes the translation and adaptation of the USA measure. It also describes the assessment of internal consistency, reproducibility, content validity, and construct validity (convergent and discriminant) of the measure. Two outcome measures of the final genital herpes-specific measure were developed: (1) a 21-item symptoms subscale; and (2) a 20-item HRQOL subscale. Each measure was scored and analyzed separately; the psychometric testing discussed in this paper refers to the HRQOL subscale only. The internal consistency of the HRQOL subscale is high (r=0.93), as is the reproducibility measured with a two week interval (r=0.85). Convergent validity is moderate to high. (Fleming Self-Regard subscale,r=0.48; SF-36 Social Functioning dimensionr=0.59; SF-36 Mental Health dimensionr=0.50). The number of herpes outbreaks in the past year was a significant predictor of scores on the HRQOL subscale (0–1 outbreaks, mean=82.1; 2+ outbreaks, mean=72.1,p=0.058) suggesting discriminant validity. The measure is currently in a phase III clinical trial including anti-viral therapy where the question of responsiveness can be addressed.

Key words

Cross-cultural genital herpes health-related quality of life reliability validation